Will Ulta Beauty's FY2026 full-year comparable store sales growth exceed 3.0%?

FY2026 comp guidance of +2.5-3.5% places the midpoint precisely at the 3.0% threshold. ULTA has a demonstrated pattern of conservative guidance — FY2025 was initially guided ~5% and delivered +5.4%, with beat-and-raises throughout the year. This suggests management's 2.5-3.5% range may have upside. However, the deceleration from 5.4% to a 3.0% midpoint is substantial, and management explicitly flagged harder H2 comps and macro uncertainty. The beauty industry growth estimate of 2-4% sets a lower ceiling. Rare Beauty is a tailwind but one brand launch cannot offset a macro slowdown. This is essentially a coin flip — guidance midpoint sits right on the threshold, and ULTA's conservative guidance history slightly favors exceeding it, but the magnitude of deceleration and macro headwinds offset that history.

The conservative guidance pattern is the key factor here. In FY2025, ULTA guided conservatively and beat throughout the year. The +2.5-3.5% range likely embeds management's typical cushion. Rare Beauty launched strong and February was described as 'pleasing' — early FY2026 data points suggest the low end of guidance is unlikely. Ticket growth at +3.3% in FY2025 shows pricing power, and transactions at +2.0% show traffic is positive. If both continue at even reduced rates, exceeding 3.0% is plausible. However, comp guidance decelerated meaningfully, beauty industry growth is moderating to 2-4%, and management noted macro uncertainty and harder H2 comps. The guidance midpoint at exactly 3.0% means this is genuinely uncertain, but ULTA's guidance track record tips it slightly above 50/50.

I weight the macro deceleration more heavily than the conservative guidance pattern. FY2025's comp recovery from +0.7% (FY2024) to +5.4% benefited from easy comparisons and pent-up demand normalization. FY2026 now faces difficult comparisons against that +5.4% comp, particularly in H2 when Q3 FY2025 delivered +6.3% and Q4 presumably delivered strongly. Management's explicit callout of harder H2 comps is notable — they are pre-conditioning for deceleration. Beauty industry growth at 2-4% constrains the upside. Stock down 13% suggests the market expects the low end of guidance. While ULTA does guide conservatively, the structural deceleration from a recovery year to a normalization year is a real dynamic, not just guidance gamesmanship.

The comp guidance range of +2.5-3.5% with a midpoint of 3.0% makes this an unusually symmetric bet. ULTA's history of conservative guidance is well-documented — they guided FY2025 to ~5% and delivered 5.4%. This pattern suggests 3.0% is more likely a floor than a ceiling. Rare Beauty is a meaningful traffic driver that was not in the comp base. February data was described positively. On the other hand, the beauty industry is moderating (2-4%), macro uncertainty is real, and the company is facing its first full year of Space NK integration which could distract from core execution. SG&A growth guidance 'in line to slightly below sales growth' suggests cost discipline but not comp-driving investment. Slightly above coin flip due to guidance conservatism pattern.

The comp question hinges on whether ULTA's FY2025 comp recovery was cyclical or structural. The data suggests a mix: ticket growth (+3.3%) reflects pricing power and premiumization (structural), while transaction growth (+2.0%) reflects traffic recovery (partially cyclical). For FY2026, the question is whether transactions sustain against +2.0% comps. Rare Beauty is a genuine traffic catalyst — the brand launched strong and is exclusive to ULTA, which should drive incremental visits. February being 'pleasing' is a positive early signal. The beauty industry at 2-4% growth means ULTA needs to take share to hit the high end of comp guidance. Their innovation pipeline (Rare Beauty, new brand additions) supports share gains. I lean slightly above 50% but this is genuinely uncertain.

Management guided comp to +2.5-3.5% which brackets the 3.0% threshold. The bears would note that management typically guides with upside but this time explicitly flagged harder H2 comps and macro uncertainty — suggesting they see less room for upside surprise than in FY2025. The -13% stock drop indicates the market found the guidance disappointing relative to FY2025 momentum. EPS guidance of $28.05-$28.55 implies comp is not the primary earnings growth driver — operating leverage and buybacks are doing more heavy lifting. If comp is not the growth engine management is optimizing for, they may prioritize margin over traffic, which could keep comp closer to the low end. Slight lean below 50%.

ULTA's conservative guidance history is the strongest signal here. FY2025 guided ~5%, delivered 5.4% with beat-and-raises. FY2026 midpoint at 3.0% likely has upside cushion. Rare Beauty and February momentum are positive early indicators. However, macro uncertainty and harder comps are headwinds. Net assessment: slightly above 50% given guidance conservatism.

Guidance midpoint sits exactly at threshold — this is inherently a 50/50 proposition until more quarters report. FY2025 comp momentum is decelerating significantly from +5.4% to guided +3.0% midpoint. Beauty industry at 2-4% constrains upside. Conservative guidance history helps but the deceleration is real. Low confidence given the extreme uncertainty.

Conservative guidance pattern plus positive early FY2026 signals (Rare Beauty, February) slightly favor exceeding 3.0%. But the comp guidance range explicitly includes outcomes below 3.0% (2.5% low end), showing management sees real downside risk. Net: slight lean toward YES given track record but high uncertainty.